Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis

Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, has announced positive topline results from its first Phase 1 clinical study of FB101. This investigational vaginal microbial immunotherapeutic has shown promising results in treating asymptomatic vaginal dysbiosis. The study was conducted in Europe and evaluated the change in vaginal microbiome after three conse..